Immunotherapy for cardiovascular disease

The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1β antibody, improves cardiovascular disease (CVD) outco...

Full description

Bibliographic Details

Published in:	European heart journal Vol. 40; no. 48; p. 3937
Main Authors:	Lutgens, Esther, Atzler, Dorothee, Döring, Yvonne, Duchene, Johan, Steffens, Sabine, Weber, Christian
Format:	Journal Article
Language:	English
Published:	England 21.12.2019
Subjects:	Cardiovascular disease Inflammation Cytokines Novel targets Novel therapies Coronary artery disease
ISSN:	1522-9645, 1522-9645
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!